Skip to content
November 16, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Global Breast Cancer Awareness
  • WHO Halts Hydroxychloroquine and Lopinavir/Ritonavir Arms in Global Solidarity Trial
  • Global Breast Cancer Awareness

WHO Halts Hydroxychloroquine and Lopinavir/Ritonavir Arms in Global Solidarity Trial

Nana November 16, 2026 7 minutes read
who-halts-hydroxychloroquine-and-lopinavir-ritonavir-arms-in-global-solidarity-trial-1

Introduction: A Strategic Pivot in the Fight Against COVID-19

In a significant development for global public health, the World Health Organization (WHO) announced today the immediate discontinuation of two primary treatment arms within its ambitious "Solidarity Trial." After a comprehensive review by the International Steering Committee, the organization has determined that hydroxychloroquine and lopinavir/ritonavir provide little to no benefit in reducing mortality rates among hospitalized COVID-19 patients compared to the standard of care.

This decision marks a pivotal moment in the scientific community’s efforts to identify effective therapeutic interventions for the virus. While the move concludes a specific chapter of the global research effort, it underscores the necessity of rigorous, evidence-based clinical trials in the face of a rapidly evolving pandemic.


Main Facts: The Evidence-Based Decision

The Solidarity Trial, a massive international effort spearheaded by the WHO, was designed to test potential repurposed drugs for the treatment of COVID-19. The study aimed to provide rapid, reliable answers to the most critical questions regarding patient outcomes.

The International Steering Committee’s recommendation was based on interim results derived from the trial itself, coupled with an exhaustive review of global clinical evidence presented during the WHO Summit on COVID-19 Research and Innovation held on July 1–2.

Key findings include:

  • Lack of Efficacy: Neither hydroxychloroquine nor lopinavir/ritonavir showed a statistically significant reduction in mortality for hospitalized patients compared to those receiving standard care.
  • Immediate Cessation: Investigators involved in the Solidarity Trial have been instructed to stop the administration of these specific drugs to new participants immediately.
  • Safety Considerations: While the interim results did not provide conclusive evidence of increased mortality directly linked to these drugs, the "Discovery" trial—a sub-study under the Solidarity umbrella—reported specific safety signals in clinical laboratory findings. These findings will be detailed in the upcoming peer-reviewed publication of the interim results.

Chronology: The Arc of the Solidarity Trial

To understand the gravity of this decision, one must look at the timeline of the Solidarity Trial, which was conceived in the early months of 2020 as the world grappled with the unprecedented spread of SARS-CoV-2.

Early 2020: The Inception of Solidarity

As cases surged globally, the WHO recognized that fragmented, small-scale studies would not provide the definitive answers required to treat a pandemic. The Solidarity Trial was launched to aggregate thousands of patients across dozens of countries, creating a platform capable of detecting even modest treatment effects.

Spring 2020: The Height of Hype

During the initial months of the pandemic, hydroxychloroquine—a drug typically used for malaria and autoimmune conditions—gained immense international attention. Despite a lack of robust clinical data, it was widely discussed as a potential "miracle" cure. Similarly, lopinavir/ritonavir, an HIV medication, was hypothesized to inhibit the viral protease of SARS-CoV-2.

July 1–2, 2020: The Summit and the Verdict

The WHO Summit on COVID-19 Research and Innovation served as a crucible for data. Leading researchers from across the globe presented their findings. It was here that the accumulated evidence—combined with the interim results of the Solidarity Trial—reached a tipping point. The data were clear: the drugs were not achieving the clinical endpoints promised in earlier, smaller, or observational studies.


Supporting Data: Why the Trial Was Halted

The scientific community often relies on the distinction between observational studies and randomized controlled trials (RCTs). The Solidarity Trial is a massive RCT, the gold standard of clinical evidence.

Analyzing the Mortality Data

The primary endpoint of the trial was all-cause mortality. When comparing the treatment groups (hydroxychloroquine and lopinavir/ritonavir) to the control group (standard of care), the statistical analysis showed no significant survival benefit. The "relative risk" of death did not decrease in a meaningful way for patients receiving these drugs.

Addressing Safety Signals

Beyond efficacy, the WHO remained vigilant regarding patient safety. The Discovery trial, which operates in coordination with the Solidarity framework, identified concerns in laboratory markers during treatment. While not necessarily translating to higher mortality in the interim data, these markers suggested physiological impacts that necessitated the termination of the treatment arms to prevent unnecessary harm to hospitalized participants.


Official Responses and Expert Commentary

The decision to halt these arms has been met with both support from the scientific community and a call for transparency.

The WHO Perspective

Daniela Bagozzi, Senior Information Officer at the WHO, emphasized that this decision is a testament to the integrity of the scientific process. "The Solidarity Trial was built on the principle of transparency and rapid knowledge sharing," the organization stated. By acting on interim data rather than waiting for the trial’s final completion, the WHO has prioritized patient safety and the responsible allocation of research resources.

The Scientific Community

Epidemiologists and infectious disease experts have lauded the move. Many argue that this highlights the danger of relying on anecdotal evidence or early, non-randomized studies. Dr. Maria Van Kerkhove, WHO Technical Lead for COVID-19, has consistently reminded the public that clinical trials are the only way to prove a drug works—or to prove it does not.


Implications: Where Does the Research Go From Here?

The termination of these arms is not a failure of the Solidarity Trial; rather, it is a successful demonstration of its primary function: to filter out ineffective treatments quickly so that global focus can shift to more promising candidates.

1. Focus on Other Therapeutics

With hydroxychloroquine and lopinavir/ritonavir removed from the equation, the Solidarity Trial continues to investigate other treatments, such as remdesivir and interferon-beta, which may hold more promise for hospitalized patients.

2. Clarifying the Scope

The WHO has been explicit: this decision applies strictly to hospitalized patients. It does not preclude researchers from studying these drugs in other contexts, such as early-stage outpatient treatment or as a prophylactic (preventative) measure. However, these studies must be conducted under rigorous, controlled conditions.

3. The Peer-Review Process

The WHO is currently preparing the interim results for publication in a major, peer-reviewed medical journal. This will allow the broader scientific community to dissect the data, fostering a deeper understanding of why these drugs failed to meet expectations in the context of COVID-19.

4. A Lesson for Future Pandemics

The Solidarity Trial has established a blueprint for global collaboration. By streamlining the process of testing drugs, the WHO has demonstrated that international solidarity in research is not just an ideal—it is a practical necessity for global health security.


Conclusion: The Path Forward

The removal of hydroxychloroquine and lopinavir/ritonavir from the Solidarity Trial is a sober reminder of the complexities of clinical research. In the heat of a pandemic, the desire for a quick fix is natural, but the responsibility to ensure that treatments are both safe and effective is paramount.

As the world continues to battle COVID-19, the Solidarity Trial remains an essential pillar of the global response. By systematically evaluating potential therapies, the WHO is ensuring that limited resources are directed toward interventions that can truly save lives. The focus now turns to the remaining arms of the trial and the continuous, rigorous analysis of the next generation of potential treatments.

The scientific journey is long and often characterized by the elimination of what does not work, but it is precisely this process of elimination that eventually leads to the discovery of what does. The Solidarity Trial continues, with the global scientific community more determined than ever to find the answers that will finally bring this pandemic to an end.

About the Author

Nana

Author

View All Posts

Post navigation

Previous: A Paradigm Shift in Cancer Immunotherapy: Mount Sinai Scientists Target Tumor Protectors, Not Just the Tumors Themselves

Related Stories

the-global-quest-for-origins-who-initiates-scientific-mission-to-china-to-unravel-sars-cov-2-roots
  • Global Breast Cancer Awareness

The Global Quest for Origins: WHO Initiates Scientific Mission to China to Unravel SARS-CoV-2 Roots

Layla Zulfa November 16, 2026
bridging-frontiers-breast-cancer-canada-showcases-global-leadership-at-esmo-2026
  • Global Breast Cancer Awareness

Bridging Frontiers: Breast Cancer Canada Showcases Global Leadership at ESMO 2026

Jia Lissa November 16, 2026
global-accountability-who-launches-independent-panel-to-deconstruct-the-covid-19-pandemic-response
  • Global Breast Cancer Awareness

Global Accountability: WHO Launches Independent Panel to Deconstruct the COVID-19 Pandemic Response

Ammar Sabilarrohman November 16, 2026

Recent Posts

  • WHO Halts Hydroxychloroquine and Lopinavir/Ritonavir Arms in Global Solidarity Trial
  • A Paradigm Shift in Cancer Immunotherapy: Mount Sinai Scientists Target Tumor Protectors, Not Just the Tumors Themselves
  • Aclaris Therapeutics’ Bosakitug Fails to Meet Primary Endpoints in Atopic Dermatitis Phase II Trial, Shifting Focus to Oral Kinase Inhibitors
  • Beyond the Checkbook: Unlocking Transformative Impact Through Gifts-in-Kind
  • Breakthrough in Breast Cancer Survivorship: Nutritional Supplement Shows Promise in Reversing ‘Brain Fog’

Recent Comments

No comments to show.

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

who-halts-hydroxychloroquine-and-lopinavir-ritonavir-arms-in-global-solidarity-trial-1
  • Global Breast Cancer Awareness

WHO Halts Hydroxychloroquine and Lopinavir/Ritonavir Arms in Global Solidarity Trial

Nana November 16, 2026
a-paradigm-shift-in-cancer-immunotherapy-mount-sinai-scientists-target-tumor-protectors-not-just-the-tumors-themselves
  • Medical Research and Clinical Trials

A Paradigm Shift in Cancer Immunotherapy: Mount Sinai Scientists Target Tumor Protectors, Not Just the Tumors Themselves

Dwi Wanna November 16, 2026
aclaris-therapeutics-bosakitug-fails-to-meet-primary-endpoints-in-atopic-dermatitis-phase-ii-trial-shifting-focus-to-oral-kinase-inhibitors
  • Medical Research and Clinical Trials

Aclaris Therapeutics’ Bosakitug Fails to Meet Primary Endpoints in Atopic Dermatitis Phase II Trial, Shifting Focus to Oral Kinase Inhibitors

Asep Darmawan November 16, 2026
beyond-the-checkbook-unlocking-transformative-impact-through-gifts-in-kind
  • Patient Advocacy and Support

Beyond the Checkbook: Unlocking Transformative Impact Through Gifts-in-Kind

Pevita Pearce November 16, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.